Vitamin D has a preventive effect on liver cancer

Share This Post

Research reports published in the Journal of Cancer Epidemiology, Biomarkers, and Prevention show that there is a negative correlation between circulating 25-hydroxyvitamin D [25 (OH) D] levels and liver cancer risk and chronic liver disease mortality To associate. Gabriel Y. Lai, author of the Department of Cancer Control and Population Science at the National Cancer Institute, and colleagues say that there has been a link between reduced vitamin D levels and chronic liver disease and liver cancer observed in laboratory studies, but there has been little epidemiology Research assesses these associations.

The study included 854 male Finnish smokers who participated in alpha-tocopherol, beta-carotene cancer prevention studies and measured vitamin D levels from their serum samples. During nearly 25 years of follow-up, 202 patients were diagnosed with liver cancer and 225 patients died of liver disease. 427 subjects without liver disease or liver cancer served as controls. Among subjects with a serum 25 (OH) D concentration of less than 10 ng / mL (ng / mL), the risk of liver cancer increased by 91% compared with those with a concentration level greater than 20 ng / mL, chronic The risk of liver disease death increased by 67%.

“Our results suggest that vitamin D may have a preventive effect on liver cancer and chronic liver disease,” Dr. Lai and colleagues concluded. “Future studies need to assess the relationship between vitamin D and liver cancer and liver disease in other populations, especially those with different Risk factors.”

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy